Sunday, 23 June |
|
|---|---|
11:00-14:00 |
SHVM Board Meeting |
14:00-18:00 |
Registration |
14:30-16:30 |
Trainee Workshop sponsored by Elsevier
Speakers: |
16:45-17:45 |
Oroboros Workshop |
Opening Session |
|
18:00-18:15 |
Welcome to Amsterdam |
18:15-19:15 |
Keynote Lecture |
19:15-21:00 |
Informal dinner reception |
Monday, 24 June |
|
|---|---|
Session 1 — Targeting cardiac fatty acid metabolism |
|
8:30-9:00 |
Sander Houten (New York, NY, USA) |
9:00-9:30 |
L. Ashley Cowart (Richmond, VA, USA) |
9:30-9:45 |
Short talk: Marina Makrecka-Kuka
(Riga, Latvia) |
9:45-10:00 |
Short talk: Laurent Bultot (Brussels, Belgium) |
10:00-10:30 |
Coffee break |
| Chairs: Michael Schwarzer (Jena, Germany), Adam Wende (Birmingham, AL, USA) | |
10:30-11:00 |
Matthieu Ruiz (Montreal, Canada) |
11:00-11:30 |
Joost Luiken (Maastricht, Netherlands) |
11:30-11:45 |
Short talk: Iain Scott (Pittsburgh, PA, USA) |
11:45-12:00 |
Short talk: Ilvy Geraets (Maastricht, Netherlands) |
12:00-13:00 |
Working Lunch sponsored by QIAGEN Jean-Noel Billaud (QIAGEN Bioinformatics, Redwood City, CA, USA) |
Session 2 — Targeting whole-body glucose metabolism: SGLT2 inhibitors for DM and HF treatment
|
|
13:00-13:30 |
Juan Badimon (New York, NY, USA) |
13:30-14:00 |
Michael Lehrke (Aachen, Germany) |
14:00-14:30 |
Julian Mustroph (Regensburg, Germany) |
14:30-14:45 |
Short talk: Salva Yurista (Groningen, Netherlands) |
14:45-15:00 |
Short talk: Paul Wijnker (Amsterdam, Netherlands) |
15:00-16:30 |
Poster Session I (with coffee and refreshments) |
17:30-23:00 |
Discover Amsterdam: |
Tuesday, 25 June |
|
|---|---|
8:30-9:30 |
Special Keynote Lecture / Dutch Heart Foundation Lecture |
9:30-10:00 |
Coffee break |
Session 3 — Metabolic targets to combat cardiac IR injury
|
|
10:00-10:30 |
Lisa Heather (Oxford, United Kingdom) |
10:30-11:00 |
Thomas Krieg (Cambridge, United Kingdom) |
11:00-11:30 |
Ioanna Andreadou (Athens, Greece) |
11:30-11:45 |
Short talk: Shubham Soni (Edmonton, AB, Canada) |
11:45-12:00 |
Short talk: Neoma Boardman (Tromsø, Norway) |
12:00-13:00 |
Lunch |
13:15-14:30 |
Poster Session II |
Session 4 — Novel approaches for metabolic modulation
|
|
14:30-15:00 |
Thomas Pulinilkunnil (Saint John, NB, Canada) |
15:00-15:30 |
Mathias Mericskay (Paris, France) |
15:30-15:45 |
Short talk: Vincent Portero (Amsterdam, Netherlands) |
15:45-16:00 |
Short talk: Yun Chen (New York, NY, USA) |
16:00-16:30 |
Coffee break |
Session 5 — The "William C. Stanley" Early Investigator Awards
|
|
16:30-16:45 |
Cláudia Correia (Skövde, Sweden) |
16:45-17:00 |
Matt Kerr (Oxford, United Kingdom) |
17:00-17:15 |
Mark Pepin (Birmingham, AL, USA) |
17:15-17:30 |
Laween Uthman (Amsterdam, Netherlands) |
19:30 |
Dinner (congress venue), followed by Amsterdam DJ |
Wednesday, 26 June |
|
|---|---|
9:00-10:00 |
"William C. Stanley" Award Lecture |
10:00-10:30 |
Coffee break |
Session 6 - MitoROS as main driver of cardiac diseases?
|
|
10:30-10:55 |
Heiko Bugger (Graz, Austria) |
10:55-11:20 |
Jolanda van der Velden (Amsterdam, Netherlands) |
11:20-11:45 |
Christoph Maack (Würzburg, Germany) |
11:45-12:00 |
Short talk: Helena Kenny (Iowa City, IA, USA) |
12:00-12:15 |
Short talk: Jaetaek Kim (Seoul, South Korea) |
12:15-12:30 |
Invitation to SHVM 2020 |
12:30-12:45 |
Concluding Remarks |
12:45 |
Buffet lunch and Adjourn |
When preparing your poster, please remember that its maximum size is A0 (841 x 1189 mm; width x height). Note that the orientation is portrait, not landscape.
Correct format... 
Wrong format...
You are expected to have your poster up the latest by lunchtime of the day of your session. Posters should be taken down after your session. Posters left behind will be removed and discarded by the venue personnel.
Poster presenters are required to be available for discussion during their assigned session. The distribution of posters in the two sessions is indicated below.
P1.1 · Azrul Abdul Kadir (Oxford, United Kingdom)
Ketone body oxidation depends on anaplerosis from asparagine in isolated rat hearts lacking pyruvate precursors
P1.2 · Rebecca K. Autenried (Iowa City, IA, USA)
Analysis of insulin signaling pathways in failing human hearts reveals differential signaling to ERK and mTOR
P1.3 · Neoma T. Boardman (Tromsø, Norway)
Obese and diabetic hearts are protected from adverse effects of an acute high FA-load
P1.4 · Cathrine Furuheim Bryn (Tromsø, Norway)
Metabolic effects of breast cancer therapy on H9c2-myoblasts
P1.5 · Laurent Bultot (Brussels, Belgium)
Increase in protein acetylation, a hallmark of cardiac metabolic stress by metabolic overfueling. The example of cardiac glucose uptake inhibition by fatty acids
P1.6 · Yun Chen (New York, NY, USA)
Regulation of the mitochondrial ATP synthase by chaperone-mediated autophagy: a novel pathway to heart failure
P1.7 · Cláudia Correia (Skövde, Sweden)
Integration of metabolic and transcriptomic profiling of chronic ischemic heart failure reveals potential therapeutic targets for cardiac dysfunction
P1.8 · Sanda Despa (Lexington, KY, USA)
SGLT-mediated Na+ overload results in oxidative stress and abnormal SR Ca2+ release in diabetic hearts
P1.9 · Laura C. Ferté (Brussels, Belgium)
Contribution of SGLT1 on cardiac glucose transport
P1.10 · Ilvy M.E. Geraets (Maastricht, Netherlands)
Metabolic interventions to treat hypertrophy-induced contractile dysfunction in vitro
P1.11 · Estelle Heyne (Jena, Germany)
Unexpected differences in respiratory capacity between human ventricle and atrium
P1.12 · Patrycja Kaczara (Krakow, Poland)
Metabolic plasticity of primary liver sinusoidal endothelial cells (LSECs)
P1.13 · Helena C. Kenny (Iowa City, IA, USA)
Inducible deletion of OPA1 in the heart induces ER stress that precedes mitochondrial and contractile dysfunction
P1.14 · Hyoung Kyu Kim (Busan, South Korea)
Heart mimetic cyclic stretch increased mitochondria biogenesis in cardiac cell line
P1.15 · Amber Korn (Amsterdam, Netherlands)
Liraglutide decreases ICAM-1 and VCAM-1 expression in the heart of streptozotocin-induced diabetic rats
P1.16 · Veronique A. Lacombe (Stillwater, OK, USA)
Glial growth factor 2 regulates glucose transport in healthy cardiac myocytes and during myocardial infarction via an Akt-dependent pathway
P1.17 · Sibille Lejeune (Brussels, Belgium)
Heart failure with preserved ejection fraction: phenotypic differences between diabetic and non diabetic patients
P1.18 · Byung-Kwan Lim (Goesan, South Korea)
Endothelial-specific CAR deletion induce nonalcoholic fatty liver diseases; a novel interaction partner of APOBEC3
P1.19 · Lauriane Michel (Brussels, Belgium)
Cardiac myocyte-specific expression of beta3-adrenergic receptors sustains AMPK activation and glucose uptake while reducing hypertrophy following pressure overload
P1.20 · Chan Bae Park (Suwon, South Korea)
Defective D-lactate metabolism induce methylglyoxal accumulation and cause cardiomyopathy
P1.21 · Mark E. Pepin (Birmingham, AL, USA)
DNA methylation reprograms cardiac metabolic gene expression in end-stage human heart failure
P1.22 · Linda R. Peterson (Saint Louis, MO, USA)
Genetic underpinnings of the beneficial very long-chain ceramides 24:0 and C22:0
P1.23 · Thomas Pulinilkunnil (Saint John, NB, Canada)
Dysregulated branched-chain amino acid metabolism acts as a predictor of growth, insulin sensitivity and cardiometabolic outcomes
P1.24 · Patricia G. Rodrigues (Oporto, Portugal)
Transcriptome and miRome signatures revealed metabolism impairment in incomplete reverse remodeling
P1.25 · Pauke C. Schots (Tromsø, Norway)
Impact of anti-obesogenic interventions of the gut microbiome
P1.26 · Iain Scott (Pittsburgh, PA, USA)
Adropin treatment restores cardiac glucose oxidation in pre-diabetic obese mice
P1.27 · Aomin Sun (Maastricht, Netherlands)
Key role for phosphatidylinositol-4-kinase IIIβ, a downstream target of protein kinase D1, in cardiac contraction-induced glucose uptake
P1.28 · Marta Tomczyk (Gdansk, Poland)
An improved skeletal muscle function and altered energy metabolism in ApoE/LDLR double knock-out mice
P1.29 · Damian J. Tyler (Oxford, United Kingdom)
Hyperpolarized 13C MR spectroscopy demonstrates impaired pyruvate dehydrogenase flux in the diabetic human heart
P1.30 · Laween Uthman (Amsterdam, Netherlands)
Sodium glucose cotransporter inhibitor (SGLT2i) Canagliflozin activates AMPK and reduces IL-6 secretion in liposaccharide (LPS) stimulated human coronary artery endothelial cells (HCAECs)
P1.31 · Yongshun Wang (Hong Kong, China)
The involvement of CFTR in ATP formation and release in the heart
P1.32 · Paul Wijnker (Amsterdam, Netherlands)
Empagliflozin corrects impaired relaxation in human engineered heart tissue carrying a MYH7 mutation
P1.33 · Salva R. Yurista (Groningen, Netherlands)
Sodium-glucose co-transporter 2 inhibition with Empagliflozin improves cardiac function in non-diabetic rats with heart failure after myocardial infarction
P1.34 · Hong Zhang (Amsterdam, Netherlands)
The mitochondrial NOD-like receptor NLRX1 protects against severe ischemia-reperfusion damage in isolated mouse hearts, with protection associated with increased Akt signaling and decreased lactate metabolism
P1.35 · Barbara Huisamen (Tygerberg, South Africa)
ATM regulates cardiac mitochondrial oxidative phosphorylation potential
P2.1 · Rio Juni (Amsterdam, Netherlands)
Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin
P2.2 · Ot Bakermans (Amsterdam, Netherlands)
Cardiac MR imaging and spectroscopy in long-chain fatty acid β-oxidation deficiency
P2.3 · Marijke Brink (Basel, Switzerland)
Neuregulin-1 stimulates glucose uptake in neonatal rat cardiomyocytes
P2.4 · Ryszard T. Smolenski (Gdansk, Poland)
Dysfunction of cardiac mitochondria in genetic model of hyperlipidemia: role of Complex I
P2.5 · John Chatham (Birmingham, AL, USA)
Cross-talk between nicotinamide adenine dinucleotide (NAD) and O-linked N-acetylglucosamine signaling (O-GlcNAc)
P2.7 · Christine Des Rosiers (Montreal, QC, Canada)
Using comprehensive plasma metabolomics to decipher metabolic abnormalities in patients with heart failure with preserved ejection (HFpEF): a proof-of-concept discovery study
P2.8 · Jan A. Dudek (Würzburg, Germany)
Defects in mitochondrial cardiolipin remodeling affects cardiac metabolism and cellular signaling in Barth syndrome
P2.9 · Mitchell D. Fiet (Amsterdam, Netherlands)
Clusterin is present in viable cardiomyocytes after viral myocarditis in patients and mice: indicative of an aberrant myocardium?
P2.10 · Dale J. Hamilton (Houston, TX, USA)
Cardiomyocyte elasticity is impaired in diastolic dysfunction in estrogen-deficient mice
P2.11 · Raffaella Isola (Monserrato, CA, Italy)
Diabetes causes right ventricle cardiac mitochondrial impairment
P2.12 · Helena C. Kenny (Iowa City, IA, USA)
Cardiac specific overexpression of transcription factor EB (TFEB) results in cardiac hypertrophy, contractile dysfunction and induction of mTOR signaling
P2.13 · Matt Kerr (Oxford, United Kingdom)
Energetic dysfunction in the type 2 diabetic myocardium is rescued by the deacetylase activator honokiol
P2.14 · Jaetaek Kim (Seoul, South Korea)
RANKL blockade suppresses pathological angiogenesis and vascular leakage in an oxygen-induced retinopathy model
P2.15 · Kamil Kus (Krakow, Poland)
Glutamine–dependent metabolic pathways in the regulation of the release of eicosanoids by vascular endothelial cells
P2.16 · Veronique A. Lacombe (Stillwater, OK, USA)
The novel role of the insulin-sensitive glucose transporter 8 in the healthy and diabetic heart
P2.17 · Edgars Liepins (Riga, Latvia)
Constitutional deletion of N6-trimethyllysine dioxygenase protects against ischemia-reperfusion-induced damage in mice hearts
P2.18 · Craig Lygate (Oxford, United Kingdom)
Consequences of elevating myocardial adenylate kinase 1 activity in mice: unexpected effects on heart weight and function, metabolomics and response to ischaemia / reperfusion
P2.19 · Michael Lehrke (Aachen, Germany)
The GLP-1(9-37) metabolite reduces myocardial glucose uptake and improves cardiac function in a model of pressure overload-induced heart failure by an improved mitochondrial biogenesis
P2.20 · Yongseek Park (Seoul, South Korea)
Cytoprotective effects of Korean Red Ginseng through induction of TrxR1 in human endothelial cells
P2.21 · Linda R. Peterson (Saint Louis, MO, USA)
Association of circulating ceramides with cardiac structure and function in the general population: The Framingham Heart Study
P2.22 · Vincent Portero (Amsterdam, Netherlands)
Branched chain amino acid (BCAA) metabolism: a new link between metabolic syndrome and cardiac arrhythmias
P2.23 · Edith Renguet (Brussels, Belgium)
Focus on tubulin acetylation, a new process to modulate glucose metabolism in diabetic heart
P2.24 · Christina Schenkl (Jena, Germany)
IGF-1 receptor inhibition by small molecule NVP-AEW541 leads to impaired systemic glucose tolerance and reversible cardiac contractile dysfunction
P2.25 · Michael Schwarzer (Jena, Germany)
Genetic predisposition for low intrinsic exercise capacity also impairs exercise induced changes in respiratory capacity
P2.26 · Shubham Soni (Edmonton, AB, Canada)
Skeletal muscle-specific knock-out of SCOT prevents the decline in cardiac function during heart failure
P2.27 · Kerstin N. Timm (Oxford, United Kingdom)
Doxorubicin treatment in rats leads to heart failure following mitochondrial loss which is not caused by oxidative stress
P2.28 · Marta Tomczyk (Gdansk, Poland)
An unexpected link between ecto-5’-nuclotidase (CD73) deficiency and vitamin B12 function in the heart
P2.29 · Laween Uthman (Amsterdam, Netherlands)
Empagliflozin acutely increases bicarbonate (HCO3-) and glucose uptake in healthy and diabetic isolated mouse hearts
P2.30 · Shujin Wang (Maastricht, Netherlands)
Assembly of vacuolar H+-ATPase as target to counteract lipid accumulation and restore contractile function in the diabetic heart
P2.31 · Magdalena A. Zabielska (Gdansk, Poland)
Genetic modification that leads to a reduction of cardiac AMP deaminase activity is cardioprotective in acute oxygen deprivation by improved cellular energetics
P2.32 · Xiang Xie (Wenzhou, China)
Pharmacologic Inhibition of FoxO1 ameliorated diabetes-related adverse vascular remodeling by attenuating NLRP3 inflammasome-dependent low-grade chronic inflammatory states
P2.33 · Herman J. Kempen (Basel, Switzerland)
Successful treatment of established heart failure in mice with recombinant ApoA1Milano/POPC (MDCO-216)
P2.34 · Barbara Huisamen (Tygerberg, South Africa)
Effects of a green Aspalathus linearis extract on obesity-related co-morbidities – possible SGLT2 inhibition
P2.35 · Berna Güven (Ankara, Turkey)
Metabolic effects of carvedilol through β-arrestin-2: investigations in cells and streptozotocin-diabetic rats